AUTHOR=Li Qizheng , Zhang Xia , Fan Buqun , Yang Yudie , Cui Xiaonan , Zhang Jie , Jiang Kaiteng , Zhang Chunxia , Zhang Bin 

TITLE=Anlotinib combined with TAS-102 as the third-line treatment for a patient with metastatic colon cancer: A case report

JOURNAL=Frontiers in Oncology

VOLUME=Volume 12 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.978005

DOI=10.3389/fonc.2022.978005

ISSN=2234-943X

ABSTRACT=Chemotherapy combined with targeted therapy is a first-line and second-line treatment for metastatic colorectal cancer, which has brought survival benefits to mCRC patients in the era of non-immunotherapy, however, disease progression is inevitable. After the failure of second-line chemotherapy, treatment compliance and the physical tolerance of patients both decrease. Choosing an appropriate third-line treatment regimen is key to prolonging survival and improving quality of life. The few side effects of TAS-102(a novel cytotoxic antitumor drug) has become the main reason for patients to choose the drug, clinical trial data for progression free survival are lacking. The exploration of third-line treatment regimens with drug combinations has attracted much attention.
This article reports a case of metastatic colon cancer, the patient was eventually treated with anlotinib combined with TAS-102 as the third-line treatment. The treatment has shown good efficacy, with a long PFS benefit and mild adverse reactions. We believe that anlotinib combined with TAS-102 is a promising third-line treatment regimen for refractory mCRC, and we hope to provide a reference for the clinical exploration of optimal third-line combination treatment regimens.